Biotech | January 12, 2026
Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The integration unifies brand and field strategy, drives executional alignment, and delivers immediate impact measurement
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
Vanda strongly disputes the FDA’s reasoning
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
Subscribe To Our Newsletter & Stay Updated
